155 related articles for article (PubMed ID: 25212538)
21. New perspectives in ovarian cancer treatment.
Schmid BC; Oehler MK
Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827
[TBL] [Abstract][Full Text] [Related]
22. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
23. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
24. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
26. Second-line treatment of first relapse recurrent ovarian cancer.
Chua TC; Liauw W; Robertson G; Morris DL
Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
[TBL] [Abstract][Full Text] [Related]
27. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
[TBL] [Abstract][Full Text] [Related]
29. Gynecologic malignancies.
Schilder RJ; Scher RM; Young RC
Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
Agarwal R; Kaye SB
Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
[TBL] [Abstract][Full Text] [Related]
31. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.
Tropé C; Kaern J
J Clin Oncol; 2007 Jul; 25(20):2909-20. PubMed ID: 17617522
[TBL] [Abstract][Full Text] [Related]
33. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
34. Nanocarriers for the targeted treatment of ovarian cancers.
Tomasina J; Lheureux S; Gauduchon P; Rault S; Malzert-Fréon A
Biomaterials; 2013 Jan; 34(4):1073-101. PubMed ID: 23174141
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemotherapy for epithelial ovarian carcinoma.
Christian MC; Trimble EL
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S143-50. PubMed ID: 7835799
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Helou K; Horvath G
Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
[TBL] [Abstract][Full Text] [Related]
38. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
39. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
Carmignani CP; Sugarbaker PH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
